| Assessment Status | Rapid Review Complete |
| HTA ID | 23032 |
| Drug | Niraparib in combination with abiraterone acetate |
| Brand | Akeega® |
| Indication | Niraparib in combination with abiraterone acetate and prednisone/prednisolone is indicated for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated. |
| Assessment Process | |
| Rapid review commissioned | 06/06/2023 |
| Rapid review completed | 11/07/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that niraparib in combination with abiraterone acetate not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
